Sandra is the Chief Development Officer of Diagonal Therapeutics. During her 20+ year career in biotech and pharma, she has had roles of increasing responsibility across development, development ops, strategy, portfolio & program management, and in vivo pharmacology at Wugen, Editas, Novartis, and Roche Vitamins. She has had extensive experience across therapeutics areas, including rare diseases, oncology, obesity, diabetes, and ophthalmology, as well as modalities from cell therapies, gene editing, biologics, to small molecules. She has an Advanced Certificate for Executives (ACE) in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D and MS from the University of Illinois, Urbana-Champaign, and a BS from the University of Porto, Portugal.